fabry disease

Nov 03, 2026

INOVIO’s VOCERYQ Receives FDA Accelerated Approval for Adult RRP; AbbVie Submits Etentamig Biologics License Application to FDA for R/R Multiple Myeloma; Setara Biosciences Raises $90 Million Series A to Advance Rare Disease Precision Medicines; BioMarin Expands Fabry Disease Portfolio With Exclusive Global License for Next-Generation ERT; Pfizer’s ELREXFIO Advances Multiple Myeloma Treatment With Positive Phase 3 Results

Nov 25, 2025

Novartis Secures FDA Approval for ITVISMA; Kelun-Biotech’s Phase III Study Shows Sac-TMT + Keytruda Achieves Primary Endpoint in First-Line PD-L1-Positive NSCLC; Evoke Phase 3 Trials Failed to Show a Statistically Significant Impact on Alzheimer’s Disease Progression; Sangamo Therapeutics Gets FDA Nod for Rolling BLA Submission of ST-920 in Fabry Disease; Bayer’s HYRNUO Receives FDA Accelerated Approval for Previously Treated HER2-mutant NSCLC

May 21, 2025

Unveiling Lysosomal Storage Disorders: Exploring Rare Diseases Impacting Millions Worldwide

Sep 04, 2023

Fabry Disease – A Market Perspective On The Emerging Pipeline

Mar 28, 2022

Examining the Therapeutic Advances in Fabry Disease Treatment Landscape

Aug 17, 2018

Regulatory

Newsletter/Whitepaper